CYD-TDV dengue vaccine: Systematic review and meta-analysis of efficacy, immunogenicity and safety

Isabella Piassi Godói*, Livia Lovato Pires Lemos, Vânia Eloisa De Araújo, Braúlio Cesar Bonoto, Brian Godman, Augusto Afonso Guerra Júnior

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Citations (Scopus)

Abstract

Introduction: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia®) was the first vaccine to gain regulatory approval to try and address this problem. Aim: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. Method: Meta-analysis and systematic review. Results: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events. Conclusion: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

Original languageEnglish
Pages (from-to)165-180
Number of pages16
JournalJournal of Comparative Effectiveness Research
Volume6
Issue number2
DOIs
Publication statusPublished - Mar 2017
Externally publishedYes

Keywords

  • CYD-TDV
  • dengue
  • meta-analysis
  • systematic review
  • vaccines

Fingerprint

Dive into the research topics of 'CYD-TDV dengue vaccine: Systematic review and meta-analysis of efficacy, immunogenicity and safety'. Together they form a unique fingerprint.

Cite this